UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer patients across this growing state. Ranked ?Exceptional? by the NCI at the most recent review in 2015 and with $233M in cancer- related extramural funding, UNC LCCC has an outstanding Clinical/Translational Research Program including a centralized clinical trials office complemented by a highly engaged translational component. This Lead Academic Participating Site (LAPS) application mirrors our clinical research program goal to improve cancer treatment by conducting practice-changing clinical trials and fostering research that will inform the next generation of clinical trials. UNC LCCC?s national stature in clinical research is illustrated by being one of a few centers to receive all three competitive NCI clinical research awards in the last funding cycle (an NCTN LAPS award, a tri-center UM1 grant for participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) and an NCTN Integrated Technology Science Center (ITSC) award). As a National Clinical Trials Network (NCTN) Lead Academic Participating Site, UNC LCCC plans to accomplish the following aims: (1) To provide scientific leadership and intellectual input into the creation of thoughtful, feasible trials to improve the health of cancer patients; (2) To support NCTN trials with robust accrual through our growing clinical enterprise; and (3) To provide opportunities for excellent translational science embedded into and informing NCTN trials.

Public Health Relevance

PROJECT SUMMARY UNC Lineberger Comprehensive Cancer Center seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). We have a remarkable track record of clinical research engagement and leadership, including multiple faculty members currently providing scientific leadership at the NCI and NCTN, a longstanding and exceptional commitment to and success in translational research in national trials, and a well-organized clinical trials unit to support participation in NCTN trials. Our mission is to design and perform practice-changing clinical research to benefit cancer patients of North Carolina.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA233373-01
Application #
9630931
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2019-05-01
Project End
2025-02-28
Budget Start
2019-05-01
Budget End
2020-02-29
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599